New FYCOMPA data presented at ECE

Eisai Inc. last week announced that new data on FYCOMPA (perampanel) CIII presented at the 12th European Congress on Epileptology (ECE) has shown that adjunctive use of the medication for up to two-and-a-half years has proven to deliver persistent seizure control in patients suffering from primary generalized tonic clonic (PGTC) seizures who have been poorly controlled.

This data was proven in the safety profile of Study 332. The poster presented at ECE featured the results of the Phase 3 study, which was open-label, randomized, double-blind and placebo-controlled.

"The extension study shows that patients with primary generalized tonic clonic seizures in idiopathic generalized epilepsy achieve similar clinical benefits, with consistent tolerability, to those seen previously in Study 332," Paracelsus Medical University Professor and Chair of the Department of Neurology Eugen Trinka said.

FYCOMPA has been indicated in the U.S. for the treatment of partial-onset seizures (POS) in patients who have epilepsy and are 12 years of age and older.

During the FYCOMPA trial, 138 patients were given adjunctive perampanel once a day for the span of 136 weeks. This followed a period of six weeks during which the doses were optimized during blinded conversion.